|
Balance Sheet Cash Flow Statement 1 Tower Center, 14th Fl. East Brunswick, NJ 08816 NJ Tel. 732-418-9300 Fax 732-418-0570 |
Type: Public
On the web:
http://www.savientpharma.com
Employees:
73
Employee growth: (2.7%)
Savient Pharmaceuticals aims to plump up the thin and send pesky urate crystals packing. The biopharmaceutical company is focused on two conditions: involuntary weight loss and gout. Its sole marketed product, Oxandrin, is a synthetic derivative of testosterone used to treat involuntary weight loss caused by trauma, surgery, or disease (mainly HIV). The company also distributes the generic form of the drug, known as oxandrolone, through a partnership with Watson Pharmaceuticals. Nearly all of the company's sales are made within the US. Savient's leading drug candidate in development is a treatment for gout called KRYSTEXXA (formerly Puricase).
Key numbers for fiscal year ending December, 2008:
Sales: $3.2M
One year growth: (77.3%)
Net income: ($84.2)M
Officers:
Chairman: Stephen O. Jaeger
President: Paul R. Hamelin
VP, CFO, and Treasurer: David G. Gionco
Competitors:
Par Pharmaceutical Companies
Roxane Laboratories
Sandoz International GmbH
